Subscribe to:
Post Comments (Atom)
skip to main |
skip to sidebar
Viral Matters focuses on all aspects of Direct Acting Antivirals (DAA) and Antiretrovirals in development and on the market.
Pages
Search This Blog
About Me
- Chris Barnes
- Redondo Beach, CA, United States
- A 17 year veteran of Medical Affairs and Commercial functions of the biopharma and pharmaceutical industry, with expertise in Hepatitis and HIV. christopherjbarnes10@gmail.com
Posts
Followers
Blog Archive
-
▼
2011
(194)
-
▼
May
(17)
- NY York Times "Prescriptions" blog on "The Hidden ...
- Achillion Pharmaceuticals ACH-2684 HCV Pan-Genotyp...
- Fair Pricing Coalition puts Merck and Vertex on no...
- Pill burden and HCV Direct Acting Antivirals....
- Vertex's Incivek approved by the FDA....
- FDA Approves Tibotec's New HIV Treatment, Edurant
- Medivir Announces Positive 48-week Interim Data fr...
- Merck's Hepatitis C Drug Victrelis Gets Positive O...
- Former archenemies Merck and Roche form a Hepatiti...
- TheStreet's Adam Feuerstein runs the numbers on th...
- Early H.I.V. Therapy Sharply Curbs Transmission....
- Boceprevir labeling highlights...
- Boceprevir gets FDA approval, first to market in t...
- Merck launches "Hope Against Hepatitis C" initiati...
- Aethlon Medical requests FDA meeting to expand Hem...
- A bit more info on Novartis' cyclophilin inhibitor...
- HIV Physicians Are Cautiously Optimistic About Boc...
-
▼
May
(17)
No comments:
Post a Comment